Literature DB >> 2549608

Mode of action of the quinolone antimicrobial agents: review of recent information.

D C Hooper1, J S Wolfson.   

Abstract

Recent studies concerning the mechanism of action of quinolones against DNA gyrase are reviewed. DNA gyrase is an essential bacterial enzyme known to be a primary target of quinolone agents. Quinolone-resistant alleles of both the gyrA and gyrB genes of DNA gyrase have been sequenced, and domains that affect the action of quinolones have been identified within the amino terminus of the gyrase A peptide and the midportion of the gyrase B peptide. In addition, an ATP-induced structural transition of DNA complexed with DNA gyrase was shown to be blocked by norfloxacin, but the means by which quinolones effect this change and the molecular site of quinolone binding remain unclear. Studies of structure-activity relationships of the quinolone molecule have been expanded and have included effects of quinolones on DNA gyrase. Stereochemical effects at positions 1 and 7 have been found. Substitutions at position 7 that improve potency against gram-positive bacteria have also been identified. Novel mono- and three-ring structures and an isothiazolo substitution at position 3 have broadened the range of structures known to have activity. Studies of bacterial killing by quinolones have revealed additional correlations with markers of DNA damage and additional alterations in bacteria and growth conditions that affect bacterial killing. The exact events responsible for quinolone-mediated lethality, however, remain undefined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549608     DOI: 10.1093/clinids/11.supplement_5.s902

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune.

Authors:  Grace Olusola Gbotosho; Christian T Happi; Olutayo Woranola; Oyindamola O Abiodun; Akin Sowunmi; Ayoade M Oduola
Journal:  Parasitol Res       Date:  2011-08-09       Impact factor: 2.289

4.  Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.

Authors:  R A Venezia; D M Yocum; E M Robbiano; R M Echols
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous.

Authors:  M Hui; A K H Kwok; C P Pang; S W Cheung; R C Y Chan; D S C Lam; A F B Cheng
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 6.  Mode of action of the new quinolones: new data.

Authors:  D C Hooper; J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 7.  Use of quinolones in pediatrics.

Authors:  U B Schaad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Design and Synthesis of Molecular Scaffolds with Anti-infective Activity.

Authors:  Junjia Liu; T Aaron Bedell; Julian G West; Erik J Sorensen
Journal:  Tetrahedron       Date:  2016-01-28       Impact factor: 2.457

Review 9.  Do we need an intravenous fluoroquinolone?

Authors:  D S Maddix; L Warner
Journal:  West J Med       Date:  1992-07

10.  Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.

Authors:  J S Wolfson; D C Hooper; G L McHugh; M A Bozza; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.